Answers are grounded in this paper and cite their sources.
Introduction. Total Neoadjuvant Therapy (TNT) has emerged in recent years as a promising therapeutic strategy in the management of locally advanced non-metastatic rectal cancer. It aims to improve locoregional and systemic control, increase tumor response rates, and optimize survival outcomes. Objective. This study aims to report the experience of the Medical Oncology Department of the Pierre and Marie Curie Center in the management of patients with non-metastatic mid and/or low rectal cancer treated with TNT, and to evaluate its impact on progression-free survival (PFS) and overall survival (OS). Methods. This retrospective study included 50 patients with histologically confirmed non-metastatic mid or low rectal adenocarcinoma, discussed in a multidisciplinary tumor board (MTB). All patients received neoadjuvant chemotherapy with FOLFIRINOX, FOLFOX, or CAPOX, followed by concomitant chemoradiotherapy and subsequent surgical resection. Clinical, therapeutic, and outcome data were analyzed. Results. After a median follow-up of 12 months, TNT achieved a high tumor response rate, including a notable pathological complete response (pCR) rate. Progression- free survival and overall survival were significantly improved compared to historical data. Treatment was generally well tolerated, with manageable and acceptable toxicity. Conclusion. Total Neoadjuvant Therapy in non- metastatic mid and low rectal cancer appears to be both effective and safe. It improves oncologic outcomes, particularly in terms of PFS and OS, supporting its integration into routine clinical practice.
No takes yet. Share an insight, caveat, or question.
Amarouche et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: